Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Oral Antibiotics on C. Difficile Carriage and Contamination
NCT02057198Phase 4Completed
- Sponsor
- Duke University
- Start
- Jun 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of fidaxomicin in Clostridioides difficile infection (CDI) (3 arms), sponsored by Duke University. Primary endpoint: Change in Total Median Total Colony Forming Units (CFU) of C. Difficile Identified in the Hospital Room Environment at Day 14. Started Jun 2014; status: completed.
02
Drugs
fidaxomicin
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT02057198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02057198.